DK1173548T3 - Materialer og fremgangsmåder til frembringelse af dopaminerge neuroner - Google Patents

Materialer og fremgangsmåder til frembringelse af dopaminerge neuroner

Info

Publication number
DK1173548T3
DK1173548T3 DK00929454T DK00929454T DK1173548T3 DK 1173548 T3 DK1173548 T3 DK 1173548T3 DK 00929454 T DK00929454 T DK 00929454T DK 00929454 T DK00929454 T DK 00929454T DK 1173548 T3 DK1173548 T3 DK 1173548T3
Authority
DK
Denmark
Prior art keywords
cells
neural
nurr1
neural stem
cell
Prior art date
Application number
DK00929454T
Other languages
Danish (da)
English (en)
Inventor
Ernest Arenas
Thomas Perlmann
Evan Y Snyder
Joseph Wagner
Peter Akerud
Original Assignee
Neuro Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Therapeutics Ab filed Critical Neuro Therapeutics Ab
Application granted granted Critical
Publication of DK1173548T3 publication Critical patent/DK1173548T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DK00929454T 1999-05-03 2000-04-27 Materialer og fremgangsmåder til frembringelse af dopaminerge neuroner DK1173548T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13231799P 1999-05-03 1999-05-03
PCT/EP2000/003842 WO2000066713A2 (en) 1999-05-03 2000-04-27 Materials and methods relating to neuronal development

Publications (1)

Publication Number Publication Date
DK1173548T3 true DK1173548T3 (da) 2007-10-08

Family

ID=22453462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00929454T DK1173548T3 (da) 1999-05-03 2000-04-27 Materialer og fremgangsmåder til frembringelse af dopaminerge neuroner

Country Status (10)

Country Link
US (1) US7465582B1 (de)
EP (1) EP1173548B1 (de)
JP (1) JP2002542818A (de)
AT (1) ATE364688T1 (de)
AU (1) AU4752700A (de)
CA (1) CA2371260A1 (de)
DE (1) DE60035191T2 (de)
DK (1) DK1173548T3 (de)
ES (1) ES2290032T3 (de)
WO (1) WO2000066713A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129034B2 (en) 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
WO2003037260A2 (en) * 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
EP2360241A1 (de) 2002-06-05 2011-08-24 ES Cell International Pte Ltd. Stammzellen
AU2003269354B2 (en) * 2002-09-24 2008-03-06 Neuro Therapeutics Ab Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands
KR20040079669A (ko) * 2003-03-10 2004-09-16 학교법인 한양학원 Ｎｕｒｒ1 과발현에 의한 도파민성 신경세포의 분화방법
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
EP1779867A4 (de) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd Mittel zur förderung der nervenreveneration
WO2007119180A2 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
EP1897937A1 (de) * 2006-09-07 2008-03-12 NeuroProgen GmbH Leipzig Verfahren zur Züchtung von neuralen Vorläuferzellen
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
ES2565779T3 (es) 2008-09-02 2016-04-06 Cedars-Sinai Medical Center Epítopos CD133
KR101181423B1 (ko) * 2009-01-30 2012-09-19 한양대학교 산학협력단 Ｎｕｒｒ1 변이체 발현을 이용한 개선된 도파민 신경세포의유도방법
WO2010129895A2 (en) 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
KR101358601B1 (ko) 2011-12-30 2014-02-05 한양대학교 산학협력단 도파민 뉴런의 제조 방법
EP2956544B1 (de) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Krebsimpfstoffe und impfverfahren
JP6340216B2 (ja) 2014-03-07 2018-06-06 株式会社日立ハイテクノロジーズ 走査電子顕微鏡
KR102203034B1 (ko) * 2017-11-06 2021-01-14 한양대학교 산학협력단 중뇌 유래의 성상교세포와 도파민 신경줄기세포의 공동 이식에 의한 도파민 신경세포의 이식 치료 효과 개선
JP2019106895A (ja) * 2017-12-15 2019-07-04 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
CN111484977B (zh) * 2019-01-25 2023-05-16 中国科学院脑科学与智能技术卓越创新中心 重编程产生功能性去甲肾上腺素能神经元的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
CA2200709A1 (en) 1994-09-23 1996-03-28 Samuel Weis In vitro models of cns function and dysfunction
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
WO2001088104A2 (en) 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
US20020114788A1 (en) 2000-07-27 2002-08-22 Ole Isacson Cell implantation therapy for neurological diseases or disorders

Also Published As

Publication number Publication date
DE60035191T2 (de) 2008-06-19
WO2000066713A2 (en) 2000-11-09
DE60035191D1 (de) 2007-07-26
ES2290032T3 (es) 2008-02-16
AU4752700A (en) 2000-11-17
EP1173548A2 (de) 2002-01-23
ATE364688T1 (de) 2007-07-15
EP1173548B1 (de) 2007-06-13
WO2000066713A3 (en) 2001-04-05
JP2002542818A (ja) 2002-12-17
CA2371260A1 (en) 2000-11-09
US7465582B1 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
DK1173548T3 (da) Materialer og fremgangsmåder til frembringelse af dopaminerge neuroner
Tepper et al. Heterogeneity and diversity of striatal GABAergic interneurons: update 2018
Krugers et al. Chronic stress effects on hippocampal structure and synaptic function: relevance for depression and normalization by anti-glucocorticoid treatment
Giardino et al. Hypocretin (orexin) neuromodulation of stress and reward pathways
Lennington et al. Neural stem cells and the regulation of adult neurogenesis
Rosenberg et al. Calcium signaling in neuronal development
Mercer et al. PACAP promotes neural stem cell proliferation in adult mouse brain
Suri et al. The adaptive and maladaptive continuum of stress responses–a hippocampal perspective
Garcia-Segura Hormones and brain plasticity
Santamaria et al. Dietary carotenoids block photocarcinogenic enhancement by benzo (a) pyrene and inhibit its carcinogenesis in the dark
Wotus et al. Forced desynchrony reveals independent contributions of suprachiasmatic oscillators to the daily plasma corticosterone rhythm in male rats
Yorgason et al. Frequency‐dependent effects of ethanol on dopamine release in the nucleus accumbens
Hoefflin et al. Neuronal expression of SOX2 is enriched in specific hypothalamic cell groups
Congiu et al. Opposite responses to aversive stimuli in lateral habenula neurons
WO2004029229A3 (en) Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands
Feng et al. Melatonin receptor expression in vocal, auditory, and neuroendocrine centers of a highly vocal fish, the plainfin midshipman (Porichthys notatus)
ATE242316T1 (de) Neurale transplantation durch verwendung von pluripotenten neuroepithelzellen
Léger et al. Noradrenergic neurons expressing Fos during waking and paradoxical sleep deprivation in the rat
DE60026703D1 (de) Vorrichtung zur messung und detektion von acetylen gelösst in einem fluid
Puglisi-Allegra et al. Circadian variations in stress-induced analgesia
Aizawa et al. Electrically stimulated modulation of cellular function in proliferation, differentiation, and gene expression
Fraser Exorcism rituals: Effects on multiple personality disorder patients.
Barrera et al. Galanin‐mediated anxiolytic effect in rat central amygdala is not a result of corelease from noradrenergic terminals
ATE72842T1 (de) Einrichtung zum umbau von elektrolytischen zellen des filterpressentyps in zellen mit kontinuierlich erneuerbaren aktivanoden.
Vidal et al. The role of Ca2+ channels of the L-type in neurotransmitter plasticity of cultured sympathetic neurons